Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Binding mode of the peptide YY carboxyterminus to the human Y2 receptor

Bo Xu, Silvana Vasile, Soren Ostergaard, Johan F. Paulsson, Jasna Pruner, Johan Aqvist, Birgitte S. Wulff, Hugo Gutierrez-de-Teran and Dan Larhammar
Molecular Pharmacology January 24, 2018, mol.117.110627; DOI: https://doi.org/10.1124/mol.117.110627
Bo Xu
1 Department of Nauropharmacology, Uppsala University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvana Vasile
2 Department of Cell and Molecular Biology, Uppsala University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soren Ostergaard
3 Peptide and Protein Chemistry, Novo Nordisk A/S;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johan F. Paulsson
4 Oberity Research, Novo Nordisk A/S;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jasna Pruner
1 Department of Nauropharmacology, Uppsala University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johan Aqvist
2 Department of Cell and Molecular Biology, Uppsala University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Birgitte S. Wulff
4 Oberity Research, Novo Nordisk A/S;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hugo Gutierrez-de-Teran
5 Uppsala University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan Larhammar
1 Department of Nauropharmacology, Uppsala University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Additional Files

  • Data Supplement

    • Supplemental Data -

      Supplemental Table 1 - Hydrogen bonds with more than 40% of occurrence between 32TRQRY36-NH2 (corresponding to PYY and truncated analogs peptides) and WT-hY2

      Supplemental Table 2 - Ki values of PYY-(3-36) analogues for WT-hY2 and its mutants. The Ki value of PYY-(3-36) for the WT-hY2 (0.46 nM), as determined with SPA assay method, was used as a reference to calculate the fold changes of Ki values of other analogues and mutants, indicated in parenthesis

      Supplemental Table 3 - Additional mutations generated along this project, all of which revealed to have negligible effects on PYY-(3-36) binding

      Supplemental Table 4 - Free energies of binding (in kcal/mol) of PYY for the hY2 mutants, calculated by FEP, and experimental valuesa

      Supplemental Figure 1 - Sequence alignment of the NPY and PYY peptides

      Supplemental Figure 2 - Sequence and chemical formulae of PYY and analogues

      Supplemental Figure 3 - Analysis of the secondary structure in time for PYY peptide and shorter analogues in complex with Y2

      Supplemental Figure 4 - Analysis of the secondary structure in time for PYY peptide and shorter analogues in water

      Supplemental Figure 5. Scatter plot of the calculated (Y axis) versus experimental (X axis) relative binding free energies (DDG, kcal/mol) for PYY-(3-36) to nine selected hY2 mutants compared to WT-hY2

Next
Back to top

In this issue

Molecular Pharmacology: 101 (6)
Molecular Pharmacology
Vol. 101, Issue 6
1 Jun 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Binding mode of the peptide YY carboxyterminus to the human Y2 receptor
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Binding mode of the peptide YY carboxyterminus to the human Y2 receptor

Bo Xu, Silvana Vasile, Soren Ostergaard, Johan F. Paulsson, Jasna Pruner, Johan Aqvist, Birgitte S. Wulff, Hugo Gutierrez-de-Teran and Dan Larhammar
Molecular Pharmacology January 24, 2018, mol.117.110627; DOI: https://doi.org/10.1124/mol.117.110627

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Binding mode of the peptide YY carboxyterminus to the human Y2 receptor

Bo Xu, Silvana Vasile, Soren Ostergaard, Johan F. Paulsson, Jasna Pruner, Johan Aqvist, Birgitte S. Wulff, Hugo Gutierrez-de-Teran and Dan Larhammar
Molecular Pharmacology January 24, 2018, mol.117.110627; DOI: https://doi.org/10.1124/mol.117.110627
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Therapeutic Effects of FGF23 Antagonists in Hyp Mice
  • TRPV3 and TRPV4 Channels Coassemble into Heterotetramers
  • Secretin Amino-Terminal Structure-Activity Relationships and Complementary Mutagenesis at the Site of Docking to the Secretin Receptor
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics